Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Type III secretion system (T3SS) ATPase and its homologous flagellar export ATPase are essential molecular motors in Gram-negative bacteria [7, 18]. These enzymes, often referred to as SctN and FliI respectively, belong to the AAA+ ATPase family and are located at the base of the T3SS injectisome or flagellar apparatus [5, 18]. Their primary biological function is to provide the energy required for the unfolding and translocation of effector proteins or flagellar subunits into the secretion channel [7, 13, 18]. By hydrolyzing ATP, these ATPases facilitate the dissociation of chaperone-effector complexes, which is a prerequisite for the delivery of virulence factors into host cells [7, 19, 20]. In the context of disease, these proteins are critical for the pathogenicity of various bacteria, including Salmonella, Shigella, Yersinia, and Pseudomonas [11, 12, 16, 18]. Because they are essential for virulence and motility but not for bacterial viability, they are considered high-priority targets for the development of antivirulence drugs [11, 12, 21, 25]. Small molecule inhibitors targeting these ATPases aim to "disarm" the pathogen, preventing the injection of toxins and reducing the severity of infection [1, 11, 12]. This approach offers a potential alternative to traditional antibiotics, as it may reduce the selective pressure that drives the emergence of multi-drug resistance [11, 21, 25]. Research has identified several experimental inhibitors, such as salicylidene acylhydrazides and hydroxyquinoline derivatives, which demonstrate the feasibility of targeting these enzymes [12, 21, 25]. However, achieving high selectivity to avoid inhibiting host ATPases remains a significant challenge in the development of these therapeutic agents [1, 11].
Inhibition of ATPase activity, blocking of effector protein unfolding and translocation, and prevention of T3SS assembly.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type III secretion system ATPase and flagellar export ATPase (SctN/FliI).